Skip to content

Assessment of malnutrition in patients with ulcerative colitis and effect of supplementation of Calcitriol in patients with active disease.

Assessment of prevalence and predictors of micronutrient deficiency in patients with ulcerative colitis and the effect of supplementation of active vitamin D in patients with Active Ulcerative Colitis â?? a double blind randomized placebo-controlled trial.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031675
Enrollment
60
Registered
2021-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K519- Ulcerative colitis, unspecified

Interventions

Intervention1: Calcitriol capsule with standard treatment: Intervention group 1: 0.25 mcg capsule BD of 1,25 dihydroxy Vitamin D3 + 1000 mg calcium carbonate along for 28 days with standard treatment

Sponsors

Post Graduate Institute of Medical education and Research Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed case of Ulcerative Colitis Clinical indication for standard colonoscopy/sigmoidoscopy

Exclusion criteria

Exclusion criteria: • Unable to provide informed consent Serious life-threatening co-morbidities Pregnant and breastfeeding women Patients with malignancy, serious life-threatening illnesses, renal or hepatic failure

Design outcomes

Primary

MeasureTime frame
Reduction in Mayo score from baseline at 4 weeksTimepoint: 4 weeks

Secondary

MeasureTime frame
i. â?¥ 3 point or â?¥ 30% Reduction in Mayo score from baseline at 4 weeks ii. â?¥ 2 Reduction in partial Mayo score at 2 weeks and 4 weeks. iii. Reduction from baseline in fecal calprotectin at 2 and 4 weeks iv. Reduction from baseline in CRP at 2 and 4 weeks v. Improvement in SIBDQ score at 4 weeks vi. Reduction from baseline in Robarts histopathological index (RHI) at 4 weeks vii. Failure of standard treatment requiring upgradation to steroids Timepoint: 4 weeks

Countries

India

Contacts

Public ContactAnurag Sachan

Post-Graduate Institute of Medical Education And Research

ushadutta@gmail.com8198877022

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026